Last reviewed · How we verify
NCT07511868: DASH
Digital Application for Stroke Health
NA trial testing StrokeApp in Haemorrhagic Stroke in 500 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | VASCage GmbH |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 500 |
| Start date | 1 April 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 7 locations across Austria |
Drugs / interventions tested
- StrokeApp
- Standard care — full drug profile →
Conditions studied
- Haemorrhagic Stroke — all drugs for Haemorrhagic Stroke →
- Ischaemic Stroke — all drugs for Ischaemic Stroke →
- Transient Ischemic Attack (TIA) — all drugs for Transient Ischemic Attack (TIA) →
Sponsor
VASCage GmbH
Who can join
18 and older, any sex, with Haemorrhagic Stroke or Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery. In this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07511868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Haemorrhagic Stroke
Currently open trials in the same condition.
- NCT05974111 — COAgulation Disorders in Ischaemic and Haemorrhagic Stroke · recruiting
- NCT05300997 — Translational Immunodiagnostics in Stroke (TrImS) · recruiting
Other VASCage GmbH trials
Trials by the same sponsor.
- NCT06940635 — Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stro · NA · recruiting
- NCT06813677 — Innsbruck Health Promotion Program · NA · recruiting
- NCT05741827 — YOUhealTH - a Study to Improve Cardiovascular Health in Adolescents and Adults · NA · completed
- NCT04749004 — A Randomized-Controlled Lifestyle Intervention to Increase Physical Activity Levels in Adolescents · NA · completed
- NCT04845269 — Post-Stroke Osteopathy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07511868 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VASCage GmbH
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07511868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing